Innovative Disease Models MIMETAS specializes in developing physiologically relevant 3D human disease models using organ-on-a-chip technology, positioning them as an ideal partner for pharmaceutical companies seeking advanced preclinical testing solutions.

Strategic Industry Collaborations Recent partnerships with Roche and Astellas Pharma indicate a strong foothold in immuno-oncology and disease modeling markets, opening opportunities to collaborate with other big pharma firms aiming to enhance their drug development pipelines.

Technology Leadership With innovations like the OrganoPlate UniFlow and ASC-derived organoids, MIMETAS offers cutting-edge products that can be integrated into drug testing and development workflows, providing potential opportunities for sales of advanced organ-on-a-chip systems.

Award Recognition Winning the Dutch Innovation Award 2022 enhances MIMETAS’s credibility and visibility, making it more attractive for pharma and biotech clients looking for innovative partners to accelerate their research efforts.

Growth and Funding With revenue between $1M to $10M and recent funding of $2.3M, MIMETAS is positioned for growth, presenting opportunities to introduce complementary products and expand their service offerings as they scale their operations.